$3.60
▲ +2.9% Today
as of Jul 22, 16:49 ET
Last 30 days
Recent Press Releases & News
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
GALT Stock Surges 22% — On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial
Galectin Therapeutics Says FDA Alignment Reached on Phase 3 Belapectin Trial
Overview
52-week range
$1.27
$7.13
40% of range
Avg surprise (last 2)
-4.2%
Avg reaction (last 2)
-3.1%
50% positive
Latest IV / EM
285%
EM ±65.3% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.08 | $-0.06 | -33.3% | +46.7% | -7.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.13 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.12 | $-0.16 | +25.0% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.15 | — | — | — | +1.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.18 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.20 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.19 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.24 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.15 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.09 | -$0.12 | +25.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-4M | — | $-4M | $-5M | $-8M | — | $-9M | $-11M |
| Net income | $-5M | — | $-8M | $-8M | $-10M | — | $-11M | $-12M |
| EPS (diluted) | $-0.08 | — | $-0.13 | $-0.12 | $-0.15 | — | $-0.18 | $-0.20 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $14M | $18M | $12M | $14M | $7M | $15M | $27M | $26M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $16M | $19M | $13M | $15M | $9M | $17M | $29M | $27M |
| Total assets | $16M | $20M | $13M | $16M | $10M | $17M | $29M | $28M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $146M | $146M | $136M | $133M | $122M | $121M | $121M | $110M |
| Total equity | $-132M | $-128M | $-125M | $-119M | $-114M | $-105M | $-94M | $-84M |